Amgen (NASDAQ: AMGN) Navigates Challenges with Strong Biosimilars Growth

• Amgen, a leading biotechnology firm, maintains a substantial market capitalization despite facing drug-specific challenges.
• Analyst firm BMO Capital has issued an "Outperform" rating for the stock, even as its drug Tavneos faces significant regulatory and data integrity concerns.
• The company's robust biosimilars segment, fueled by new product launches and a strong pipeline, is a key driver of growth and a potential offset to other issues.

Amgen (NASDAQ: AMGN) is a major biotechnology company that discovers, develops, and delivers human medicines. With a market capitalization of around $195.44 billion, it is a significant player in the global pharmaceutical industry, competing with other large drug manufacturers to create new treatments.

On July 1, 2026, analyst firm BMO Capital confirmed its "Outperform" rating for Amgen. This rating means the firm expects the stock to perform better than the overall market average. At the time of the rating, Amgen's stock price was $362.12 per share.

This positive outlook comes despite significant challenges for its drug, Tavneos. The New England Journal of Medicine retracted a key clinical trial article due to data concerns, as highlighted by Reuters. A European regulator also called for the drug's marketing authorization to be revoked, as highlighted by the Wall Street Journal.

However, Amgen's biosimilars business is showing strong growth, which may offset other issues. This segment generated $835 million in sales in the first quarter of 2026, a 14% increase from the previous year, as highlighted by Zacks. Biosimilars are near-identical copies of original biologic drugs.

Recent product launches like Wezlana and Pavblu are driving this growth. Amgen is also advancing its pipeline with biosimilars for major drugs like Opdivo and Keytruda. This strategy aims to capture market share from blockbuster drugs as their patents expire, providing a future source of revenue.